Today, Jody sits down once again with Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO). Ben catches us up on the progress the medical psychedelics company has made since the start of the year including FDA approval of a Phase II clinical trial to investigate the effects of Filament’s lead drug candidate in treating patients suffering from major depressive disorder.

Enjoy!